HURA

Tuhura Biosciences, Inc. (HURA) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Tuhura Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapeutics to overcome resistance to cancer immunotherapies. The company operates three distinct technology platforms: Immune Fx (IFx), VISTA-inhibiting monoclonal antibodies (TBS-2025), and Delta Opioid Receptor technology. A significant corporate event during the period was the completion of the merger with Kineta, Inc. on June 30, 2025, which added the TBS-2025 asset to the portfolio.

Key Financial Metrics

Balance Sheet Highlights (Sept 30, 2025):

• Total Assets: $25.70 million (includes $13.55 million Goodwill and $8.26 million In-process R&D from Kineta acquisition).
• Total Liabilities: $8.92 million (includes $2.78 million holdback liability payable in shares).
• Stockholders' Equity: $16.78 million.
• Accumulated Deficit: $(134.42) million.

Material Changes vs. Prior Period

• Acquisition Impact: The merger with Kineta, Inc. closed on June 30, 2025. This resulted in the recognition of $13.55 million in Goodwill and $8.26 million in In-process Research and Development (IPR&D). The acquisition also added TBS-2025 to the pipeline.
• Expense Increases: Operating expenses increased significantly year-over-year. R&D expenses rose by $2.02 million in Q3 and $5.12 million YTD, driven by the initiation of the Phase 3 trial for IFx-2.0, development of TBS-2025, and increased personnel costs. G&A expenses increased by $0.98 million in Q3 and $6.55 million YTD, largely due to merger transaction costs and increased stock-based compensation.
• Interest Expense Reduction: Interest expense dropped from $2.00 million in Q3 2024 to $16,532 in Q3 2025. This decrease is attributed to the conversion of high-interest convertible notes (TuHURA Notes) into common stock upon the completion of the Kintara Merger.
• Grant Income: The company recognized $138,299 in grant income for Q3 2025 (and $713,508 YTD) from an NIH grant assumed in the Kintara Merger, compared to zero in the prior year periods.
• Share Count: Weighted-average shares outstanding increased from ~12.2 million in Q3 2024 to ~50.7 million in Q3 2025 due to the merger and equity financings.

Guidance, Outlook, and Risks

• Liquidity and Going Concern: As of September 30, 2025, the company held $2.70 million in cash. Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional funding. The company expects existing resources, including anticipated payments from a private placement and a bridge loan, to fund operations only through the end of 2025.
• Recent Financing:
  • Private Placement: A $12.6 million offering was initiated in June 2025. As of Sept 30, $3.2 million of the final tranche was funded, with $0.5 million remaining to be purchased by December 31, 2025.
  • Bridge Loan: On October 27, 2025, the company secured a $3.0 million bridge loan facility, with an initial advance of $1.5 million received.
  • ATM Program: On November 3, 2025, the company entered into an At-The-Market (ATM) offering agreement to sell up to $50 million of common stock, pending SEC effectiveness of the S-3 registration.
• Clinical Pipeline:
  • IFx-2.0: Initiated a Phase 3 registration trial in June 2025 for Merkel cell carcinoma.
  • TBS-2025: Planning a Phase 2 trial in AML following the Kineta acquisition.
• Risks: Key risks include the inability to raise additional capital, delays in regulatory approvals (FDA), potential government shutdowns affecting FDA review timelines, and the inherent uncertainty of clinical trial outcomes. The company has no approved products and no product revenue.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $2.7 million cash balance plus the $1.5 million bridge loan advance against the projected burn rate to confirm operations can continue through 2025.
• Financing Completion: Monitor the closing of the remaining $0.5 million tranche of the June 2025 private placement and the effectiveness of the $50 million ATM program.
• Merger Accounting: Review the final purchase price allocation for the Kineta acquisition, specifically the valuation of the $8.26 million IPR&D asset and the $13.55 million Goodwill.
• Clinical Milestones: Track patient enrollment and data readouts for the IFx-2.0 Phase 3 trial and the planned TBS-2025 Phase 2 trial.
• Regulatory Environment: Assess the impact of potential government shutdowns on FDA review timelines for the company's accelerated approval pathway.